Group One Trading
GANX icon

Group One Trading’s Gain Therapeutics GANX Stock Holding History

Group One Trading’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,000
Closed -$38.8K – 7908
2026
Q1 		$38.8K Buy
+20,000
New +$43.5K ﹤0.01% 5454
2024
Q1 		– Sell
-2,000
Closed -$6.53K – 7352
2023
Q4 		$6.53K Hold
2,000
– – ﹤0.01% 6406
2023
Q3 		$6.46K Buy
+2,000
New +$7.58K ﹤0.01% 6564

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Group One Trading's GANX Position: Q2 2026 in Review

Group One Trading reduced its Gain Therapeutics (GANX) stake by 41% in Q2 2026, selling an estimated $4.79K and leaving 3,808 shares worth $7.73K. The position accounts for ﹤0.01% of the portfolio, ranked #6554.

Group One Trading first reported a position in GANX in Q2 2023 and has held it in 11 quarters since. The position peaked at $174K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Group One Trading held 3,808 shares of Gain Therapeutics worth $7.73K as of Q2 2026.
  • Group One Trading sold 2,596 Gain Therapeutics shares in Q2 2026, an estimated $4.79K.
  • Gain Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6554 holding.
  • Group One Trading first reported a position in Gain Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • Group One Trading's Gain Therapeutics position peaked at $174K in Q4 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.